Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

M&aacute;rio Rodrigues Louz&atilde;1, Helio Elkis1, Sandra Ruschel2, Irismar Reis de Oliveira3, Rodrigo Affonseca Bressan4, Paulo Belmonte-de-Abreu5, Hamilton Grabowski6, Jos&eacute; Carlos Appolin&aacute;rio71Universidade de S&atilde;o Paulo, S&atilde...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Louz&atilde; M, Elkis H, Ruschel S, de Oliveira IR, Bressan RA, Belmonte-de-Abreu P, Grabowski H, Appolin&aacute;rio JC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ac65a0cc429c475dafe29be5121d1ee8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac65a0cc429c475dafe29be5121d1ee8
record_format	dspace
spelling	oai:doaj.org-article:ac65a0cc429c475dafe29be5121d1ee82021-12-02T02:50:28ZLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia1176-63281178-2021https://doaj.org/article/ac65a0cc429c475dafe29be5121d1ee82011-06-01T00:00:00Zhttp://www.dovepress.com/long-acting-injectable-risperidone-in-partially-adherent-and-nonadhere-a7725https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021M&aacute;rio Rodrigues Louz&atilde;1, Helio Elkis1, Sandra Ruschel2, Irismar Reis de Oliveira3, Rodrigo Affonseca Bressan4, Paulo Belmonte-de-Abreu5, Hamilton Grabowski6, Jos&eacute; Carlos Appolin&aacute;rio71Universidade de S&atilde;o Paulo, S&atilde;o Paulo; 2Hospital M&aacute;rio Kroeff, Rio de Janeiro; 3Universidade Federal da Bahia, Salvador; 4Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo; 5Universidade Federal do Rio Grande do Sul, Porto Alegre; 6Hospital Bom Retiro, Curitiba; 7Janssen-Cilag Farmaceutica Ltda, S&atilde;o Paulo, BrazilBackground: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication.Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score.Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well-tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%).Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.Keywords: patient compliance, adherence, risperidone, delayed-action preparations, schizophreniaLouz&atilde; MElkis HRuschel Sde Oliveira IRBressan RABelmonte-de-Abreu PGrabowski HAppolin&aacute;rio JCDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 391-398 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Louz&atilde; M Elkis H Ruschel S de Oliveira IR Bressan RA Belmonte-de-Abreu P Grabowski H Appolin&aacute;rio JC Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
description	M&aacute;rio Rodrigues Louz&atilde;1, Helio Elkis1, Sandra Ruschel2, Irismar Reis de Oliveira3, Rodrigo Affonseca Bressan4, Paulo Belmonte-de-Abreu5, Hamilton Grabowski6, Jos&eacute; Carlos Appolin&aacute;rio71Universidade de S&atilde;o Paulo, S&atilde;o Paulo; 2Hospital M&aacute;rio Kroeff, Rio de Janeiro; 3Universidade Federal da Bahia, Salvador; 4Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo; 5Universidade Federal do Rio Grande do Sul, Porto Alegre; 6Hospital Bom Retiro, Curitiba; 7Janssen-Cilag Farmaceutica Ltda, S&atilde;o Paulo, BrazilBackground: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication.Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score.Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well-tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%).Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.Keywords: patient compliance, adherence, risperidone, delayed-action preparations, schizophrenia
format	article
author	Louz&atilde; M Elkis H Ruschel S de Oliveira IR Bressan RA Belmonte-de-Abreu P Grabowski H Appolin&aacute;rio JC
author_facet	Louz&atilde; M Elkis H Ruschel S de Oliveira IR Bressan RA Belmonte-de-Abreu P Grabowski H Appolin&aacute;rio JC
author_sort	Louz&atilde; M
title	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_short	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_full	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_fullStr	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_full_unstemmed	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_sort	long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/ac65a0cc429c475dafe29be5121d1ee8
work_keys_str_mv	AT louzampatildem longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT elkish longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT ruschels longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT deoliveirair longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT bressanra longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT belmontedeabreup longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT grabowskih longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia AT appolinampaacuteriojc longactinginjectablerisperidoneinpartiallyadherentandnonadherentpatientswithschizophrenia
_version_	1718402118075809792

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

Ejemplares similares